Novartis Launches Direct Sales Platform In US In Bid To Lower Drug Prices

2025-09-29 02:07:34

(MENAFN- Swissinfo) Novartis is starting a new chapter in US sales: On Monday, the pharmaceutical company announced that it will sell its psoriasis drug Cosentyx (secukinumab) directly to cash-paying patients in the US via a direct-to-patient (DTP) platform. This content was published on September 29, 2025 - 15:08 2 minutes Keystone-SDA

+Get the most important news from Switzerland in your inbox

This platform is set to launch on November 1, 2025. It will offer patients who have been prescribed the drug the opportunity to purchase it at a 55% discount on the list price.

According to the press release, Cosentyx is Novartis' best-selling product in the US. It is a biologic approved for the treatment of various immune-mediated inflammatory diseases.

More More Drug pricing The high stakes fight over drug prices

This content was published on Sep 19, 2025 Global drug pricing disputes are intensifying as pharma firms and regulators clash over how much a medicine is worth.

Read more: The high stakes fight over drug price

MENAFN29092025000210011054ID1110126045

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.